JP2023526836A5 - - Google Patents
Info
- Publication number
- JP2023526836A5 JP2023526836A5 JP2022570454A JP2022570454A JP2023526836A5 JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5 JP 2022570454 A JP2022570454 A JP 2022570454A JP 2022570454 A JP2022570454 A JP 2022570454A JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cov
- sars
- mek inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20175739.0A EP3912623B1 (en) | 2020-05-20 | 2020-05-20 | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| EP20175739.0 | 2020-05-20 | ||
| PCT/EP2021/063485 WO2021234097A1 (en) | 2020-05-20 | 2021-05-20 | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526836A JP2023526836A (ja) | 2023-06-23 |
| JP2023526836A5 true JP2023526836A5 (cg-RX-API-DMAC7.html) | 2024-05-30 |
Family
ID=70802645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570454A Pending JP2023526836A (ja) | 2020-05-20 | 2021-05-20 | コロナウイルス感染症および/またはcovid-19サイトカインストームの処置または予防のためのmek阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230241014A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3912623B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023526836A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013077A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116635022A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021277517A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023013A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178137A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2995196T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014561A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021234097A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3697405T1 (sl) | 2017-10-17 | 2021-11-30 | Atriva Therapeutics Gmbh | Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| WO2024073077A1 (en) * | 2022-09-30 | 2024-04-04 | 60 Degrees Pharmaceuticals Llc | Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine |
| CN116270588B (zh) * | 2022-12-26 | 2025-07-25 | 中国科学技术大学 | Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN117562890B (zh) * | 2023-08-03 | 2026-05-19 | 中国医学科学院医药生物技术研究所 | 一种色酮类化合物在制备抗冠状病毒药物中的用途 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002249261A1 (en) * | 2001-03-06 | 2002-09-19 | Axxima Pharmaceuticals Ag | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| SI3697405T1 (sl) * | 2017-10-17 | 2021-11-30 | Atriva Therapeutics Gmbh | Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-05-20 ES ES20175739T patent/ES2995196T3/es active Active
- 2020-05-20 EP EP20175739.0A patent/EP3912623B1/en active Active
-
2021
- 2021-05-20 CN CN202180059642.7A patent/CN116635022A/zh active Pending
- 2021-05-20 AU AU2021277517A patent/AU2021277517A1/en active Pending
- 2021-05-20 WO PCT/EP2021/063485 patent/WO2021234097A1/en not_active Ceased
- 2021-05-20 US US17/999,185 patent/US20230241014A1/en active Pending
- 2021-05-20 CA CA3178137A patent/CA3178137A1/en active Pending
- 2021-05-20 EP EP21731684.3A patent/EP4153159A1/en active Pending
- 2021-05-20 BR BR112022023013A patent/BR112022023013A2/pt unknown
- 2021-05-20 KR KR1020227044294A patent/KR20230013077A/ko active Pending
- 2021-05-20 MX MX2022014561A patent/MX2022014561A/es unknown
- 2021-05-20 JP JP2022570454A patent/JP2023526836A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114786659B (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| Yousefi et al. | A global treatments for coronaviruses including COVID‐19 | |
| JP5470047B2 (ja) | 抗ウイルス組成物及び使用方法 | |
| CN113244212B (zh) | 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用 | |
| KR102910416B1 (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
| EP4613275A1 (en) | Pharmaceutical use of nucleoside compound | |
| EP3934653B1 (en) | Azelastine as antiviral treatment | |
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| US4828830A (en) | Method and composition for prophylaxis and treatment of viral infections | |
| WO2017201030A1 (en) | Methods of treating viral infection | |
| RU2555765C2 (ru) | Пироксикам для профилактического и терапевтического лечения герпетических инфекций | |
| Steffenhagen et al. | Evaluation of 6-azauridine and S-iododeoxyuridine in the treatment of experimental viral infections | |
| WO2022079496A1 (en) | A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof | |
| US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
| EP4132501A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| US12171732B2 (en) | Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections | |
| CN114732815B (zh) | 一种化合物在制备抗病毒药物中的用途及应用 | |
| RU2843665C1 (ru) | Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания | |
| US20240115622A1 (en) | Formulation for the prevention and/or treatment of covid-19 | |
| CN116036084A (zh) | 千金藤素在制备治疗冠状病毒感染患者的药物中的用途 | |
| Yu et al. | Timing-specific efficacy of antiviral baloxavir and anti-inflammatory oclacitinib monotherapies, and the benefits of their combination in treating influenza in mice | |
| Sidwell et al. | Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice | |
| CN121818590A (zh) | Otx008在治疗hsv-1病毒感染中应用 | |
| HK40081976B (en) | Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease |